SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 58 filers reported holding SYROS PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 0.44 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $429,000 | -32.7% | 96,084 | -17.7% | 0.03% | -26.2% |
| Q2 2021 | $637,000 | -42.2% | 116,801 | -20.8% | 0.04% | -46.8% |
| Q1 2021 | $1,103,000 | +20.3% | 147,442 | +74.4% | 0.08% | +27.4% |
| Q4 2020 | $917,000 | +27.9% | 84,545 | +4.2% | 0.06% | +31.9% |
| Q3 2020 | $717,000 | +90.2% | 81,118 | +129.1% | 0.05% | +80.8% |
| Q2 2020 | $377,000 | +80.4% | 35,400 | +0.3% | 0.03% | +52.9% |
| Q1 2020 | $209,000 | -21.7% | 35,300 | -8.5% | 0.02% | +6.2% |
| Q4 2019 | $267,000 | +60.8% | 38,599 | +140.7% | 0.02% | +60.0% |
| Q3 2019 | $166,000 | -11.2% | 16,033 | -20.6% | 0.01% | -9.1% |
| Q2 2019 | $187,000 | -69.7% | 20,200 | -61.0% | 0.01% | -57.7% |
| Q3 2018 | $618,000 | +4.0% | 51,849 | -10.9% | 0.03% | +13.0% |
| Q2 2018 | $594,000 | -30.0% | 58,224 | -11.0% | 0.02% | -20.7% |
| Q1 2018 | $849,000 | +41.3% | 65,400 | +5.8% | 0.03% | +70.6% |
| Q4 2017 | $601,000 | -5.8% | 61,805 | +42.5% | 0.02% | -19.0% |
| Q3 2017 | $638,000 | – | 43,366 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Flagship Pioneering Inc. | 4,806,656 | $58,449,000 | 19.02% |
| Casdin Capital, LLC | 182,141 | $2,215,000 | 1.83% |
| Aisling Capital LLC | 508,565 | $6,184,000 | 1.44% |
| Redmile Group, LLC | 948,440 | $11,533,000 | 0.99% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,812,778 | $22,043,000 | 0.91% |
| EcoR1 Capital, LLC | 63,596 | $773,000 | 0.25% |
| Eventide Asset Management | 150,000 | $1,824,000 | 0.12% |
| AWM Investment Company, Inc. | 47,550 | $578,000 | 0.11% |
| Weiss Multi-Strategy Advisers LLC | 49,000 | $596,000 | 0.03% |
| Baker Brothers Advisors | 204,465 | $2,486,000 | 0.02% |